LAKOMÝ, Radek, Jiří ŠÁNA, Simona HANKEOVÁ, Pavel FADRUS, Leoš KŘEN, Marek SVOBODA and Ondřej SLABÝ. MiR-195, miR-196b, miR-181c, miR-21 expression levels and MGMT methylation status are associated with clinical outcome in glioblastoma patients. In The 16th World Congress on Advances in Oncology and 14th International Symposium on Molecular Medicine. 2011. ISSN 1107-3756.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name MiR-195, miR-196b, miR-181c, miR-21 expression levels and MGMT methylation status are associated with clinical outcome in glioblastoma patients.
Authors LAKOMÝ, Radek, Jiří ŠÁNA, Simona HANKEOVÁ, Pavel FADRUS, Leoš KŘEN, Marek SVOBODA and Ondřej SLABÝ.
Edition The 16th World Congress on Advances in Oncology and 14th International Symposium on Molecular Medicine, 2011.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher Greece
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.573
Organization unit Masaryk Memorial Cancer Institute
ISSN 1107-3756
UT WoS 000295422700270
Keywords in English glioblastoma multiforme; miR-195; miR-196b; miR-181c; miR-21; MGMT methylation
Tags International impact
Changed by Changed by: Mgr. Petra Vychytilová, Ph.D., učo 211789. Changed: 12/6/2012 13:36.
Abstract
Glioblastoma multiforme (GBM) is the most frequently occuring primary malignant brain tumor with very poor prognosis and different response to treatment. Therefore, it is very important to find new biomarkers which can predict a clinical outcomes and help in treatment decisions. MicroRNAs are small, non-coding RNAs that function as post-transcriptional regualtors of ene expression and play key role in pathogenesis of GBM.
PrintDisplayed: 20/8/2024 18:55